Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03647163
Title Combination Therapy With Intravenous VSV-IFNbeta-NIS and Pembrolizumab in Refractory NSCLC and HCC
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Vyriad, Inc.

lung non-small cell carcinoma

Advanced Solid Tumor

hepatocellular carcinoma


Pembrolizumab + VSV-hIFNbeta-NIS

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.